Form 6-K Erytech Pharma S.A. For: Jun 30

September 20, 2021 1:38 PM EDT

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
eryp-20210630
falseJun 30, 20212021Q2000162442212-3100016244222021-01-012021-06-30iso4217:EUR00016244222020-01-012020-06-30iso4217:EURxbrli:shares00016244222020-12-3100016244222021-06-3000016244222019-12-3100016244222020-06-300001624422ifrs-full:IssuedCapitalMember2019-12-310001624422ifrs-full:SharePremiumMember2019-12-310001624422ifrs-full:OtherReservesMember2019-12-310001624422ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2019-12-310001624422eryp:RetainedEarningsReportingPeriodMember2019-12-310001624422eryp:RetainedEarningsReportingPeriodMember2020-01-012020-06-300001624422ifrs-full:OtherReservesMember2020-01-012020-06-300001624422ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2020-01-012020-06-300001624422ifrs-full:IssuedCapitalMember2020-01-012020-06-300001624422ifrs-full:SharePremiumMember2020-01-012020-06-300001624422ifrs-full:IssuedCapitalMember2020-06-300001624422ifrs-full:SharePremiumMember2020-06-300001624422ifrs-full:OtherReservesMember2020-06-300001624422ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2020-06-300001624422eryp:RetainedEarningsReportingPeriodMember2020-06-300001624422ifrs-full:IssuedCapitalMember2020-12-310001624422ifrs-full:SharePremiumMember2020-12-310001624422ifrs-full:OtherReservesMember2020-12-310001624422ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2020-12-310001624422eryp:RetainedEarningsReportingPeriodMember2020-12-310001624422eryp:RetainedEarningsReportingPeriodMember2021-01-012021-06-300001624422ifrs-full:OtherReservesMember2021-01-012021-06-300001624422ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2021-01-012021-06-300001624422ifrs-full:IssuedCapitalMember2021-01-012021-06-300001624422ifrs-full:SharePremiumMember2021-01-012021-06-300001624422ifrs-full:IssuedCapitalMember2021-06-300001624422ifrs-full:SharePremiumMember2021-06-300001624422ifrs-full:OtherReservesMember2021-06-300001624422ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2021-06-300001624422eryp:RetainedEarningsReportingPeriodMember2021-06-300001624422eryp:RegisteredOfferingMember2021-01-012021-06-300001624422eryp:AtTheMarketOfferingMember2021-01-012021-06-3000016244222013-05-012013-05-3100016244222017-11-012017-11-30iso4217:USD0001624422ifrs-full:BottomOfRangeMembereryp:TRYBECATrialOneMember2021-01-012021-06-300001624422eryp:TRYBECATrialOneMemberifrs-full:TopOfRangeMember2021-01-012021-06-30xbrli:shares0001624422eryp:AtTheMarketOfferingMember2021-02-012021-02-2800016244222021-03-020001624422ifrs-full:DerivativesMember2021-03-020001624422eryp:RegisteredDirectOfferingMember2021-04-012021-04-30xbrli:pureiso4217:USDxbrli:shares0001624422eryp:RegisteredDirectOfferingMember2021-04-3000016244222021-05-190001624422ifrs-full:DerivativesMember2021-05-19eryp:tranch0001624422eryp:EuropeanHighGrowthOpportunitiesSecuritizationFundMemberifrs-full:MajorOrdinaryShareTransactionsMember2021-07-222021-08-240001624422eryp:EuropeanHighGrowthOpportunitiesSecuritizationFundMemberifrs-full:MajorOrdinaryShareTransactionsMember2021-07-220001624422eryp:EuropeanHighGrowthOpportunitiesSecuritizationFundMemberifrs-full:MajorOrdinaryShareTransactionsMember2021-08-240001624422ifrs-full:TopOfRangeMember2021-06-30eryp:uSD_per_EUR0001624422country:FR2020-01-012020-06-300001624422country:FR2021-01-012021-06-300001624422country:US2020-01-012020-06-300001624422country:US2021-01-012021-06-300001624422ifrs-full:DerivativesMembereryp:EuropeanHighGrowthOpportunitiesSecuritizationFundMemberifrs-full:MajorOrdinaryShareTransactionsMember2021-07-220001624422ifrs-full:DerivativesMembereryp:EuropeanHighGrowthOpportunitiesSecuritizationFundMemberifrs-full:MajorOrdinaryShareTransactionsMember2021-08-240001624422eryp:ResearchTaxCreditMember2020-01-012020-06-300001624422eryp:ResearchTaxCreditMember2021-01-012021-06-300001624422eryp:SubsidiesMember2020-01-012020-06-300001624422eryp:SubsidiesMember2021-01-012021-06-300001624422eryp:RevenueFromContractsWithCustomersMember2020-01-012020-06-300001624422eryp:RevenueFromContractsWithCustomersMember2021-01-012021-06-300001624422eryp:TedacProjectMember2020-06-300001624422eryp:TedacProjectMember2020-01-012020-06-300001624422eryp:ResearchTaxCreditMembereryp:TedacProjectMember2020-01-012020-06-300001624422eryp:ResearchAndDevelopmentExpensesMembereryp:ResearchAndDevelopmentMember2020-01-012020-06-300001624422eryp:ResearchAndDevelopmentExpensesMembereryp:ClinicalStudiesMember2020-01-012020-06-300001624422eryp:ResearchAndDevelopmentExpensesMember2020-01-012020-06-300001624422eryp:ResearchAndDevelopmentExpensesMembereryp:ResearchAndDevelopmentMember2021-01-012021-06-300001624422eryp:ResearchAndDevelopmentExpensesMembereryp:ClinicalStudiesMember2021-01-012021-06-300001624422eryp:ResearchAndDevelopmentExpensesMember2021-01-012021-06-300001624422eryp:GeneralAndAdministrativeExpensesMember2020-01-012020-06-300001624422eryp:GeneralAndAdministrativeExpensesMember2021-01-012021-06-30eryp:employee0001624422eryp:SO2020Member2021-06-012021-06-300001624422eryp:SO2020Member2021-06-30eryp:year0001624422eryp:SO2020Membereryp:TrancheOneMember2021-06-012021-06-300001624422eryp:SO2020Membereryp:TrancheTwoMember2021-06-012021-06-300001624422eryp:AGA2020Member2021-06-012021-06-300001624422eryp:AGA2020Member2021-06-30eryp:multiple0001624422eryp:AGAMember2020-01-012020-06-300001624422eryp:AGAMembereryp:EmployeesMember2020-01-012020-06-300001624422eryp:AGAMembereryp:ExecutiveOfficersAndExecutiveCommitteeMember2020-01-012020-06-300001624422eryp:BSAMember2020-01-012020-06-300001624422eryp:BSAMembereryp:BoardMembersMember2020-01-012020-06-300001624422eryp:SOMember2020-01-012020-06-300001624422eryp:SOMembereryp:EmployeesMember2020-01-012020-06-300001624422eryp:SOMembereryp:ExecutiveOfficersAndExecutiveCommitteeMember2020-01-012020-06-300001624422eryp:EmployeesMember2020-01-012020-06-300001624422eryp:ExecutiveOfficersAndExecutiveCommitteeMember2020-01-012020-06-300001624422eryp:BoardMembersMember2020-01-012020-06-300001624422eryp:AGAMember2021-01-012021-06-300001624422eryp:AGAMembereryp:EmployeesMember2021-01-012021-06-300001624422eryp:AGAMembereryp:ExecutiveOfficersAndExecutiveCommitteeMember2021-01-012021-06-300001624422eryp:BSAMember2021-01-012021-06-300001624422eryp:BSAMembereryp:BoardMembersMember2021-01-012021-06-300001624422eryp:SOMember2021-01-012021-06-300001624422eryp:SOMembereryp:EmployeesMember2021-01-012021-06-300001624422eryp:SOMembereryp:ExecutiveOfficersAndExecutiveCommitteeMember2021-01-012021-06-300001624422eryp:EmployeesMember2021-01-012021-06-300001624422eryp:ExecutiveOfficersAndExecutiveCommitteeMember2021-01-012021-06-300001624422eryp:BoardMembersMember2021-01-012021-06-300001624422ifrs-full:FixturesAndFittingsMemberifrs-full:GrossCarryingAmountMember2020-12-310001624422ifrs-full:GrossCarryingAmountMemberifrs-full:MachineryMember2020-12-310001624422ifrs-full:OfficeEquipmentMemberifrs-full:GrossCarryingAmountMember2020-12-310001624422ifrs-full:GrossCarryingAmountMemberifrs-full:ConstructionInProgressMember2020-12-310001624422eryp:AdvancePaymentMemberifrs-full:GrossCarryingAmountMember2020-12-310001624422ifrs-full:GrossCarryingAmountMember2020-12-310001624422ifrs-full:FixturesAndFittingsMemberifrs-full:GrossCarryingAmountMember2021-01-012021-06-300001624422ifrs-full:GrossCarryingAmountMemberifrs-full:MachineryMember2021-01-012021-06-300001624422ifrs-full:OfficeEquipmentMemberifrs-full:GrossCarryingAmountMember2021-01-012021-06-300001624422ifrs-full:GrossCarryingAmountMemberifrs-full:ConstructionInProgressMember2021-01-012021-06-300001624422eryp:AdvancePaymentMemberifrs-full:GrossCarryingAmountMember2021-01-012021-06-300001624422ifrs-full:GrossCarryingAmountMember2021-01-012021-06-300001624422ifrs-full:FixturesAndFittingsMemberifrs-full:GrossCarryingAmountMember2021-06-300001624422ifrs-full:GrossCarryingAmountMemberifrs-full:MachineryMember2021-06-300001624422ifrs-full:OfficeEquipmentMemberifrs-full:GrossCarryingAmountMember2021-06-300001624422ifrs-full:GrossCarryingAmountMemberifrs-full:ConstructionInProgressMember2021-06-300001624422eryp:AdvancePaymentMemberifrs-full:GrossCarryingAmountMember2021-06-300001624422ifrs-full:GrossCarryingAmountMember2021-06-300001624422ifrs-full:FixturesAndFittingsMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2020-12-310001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:MachineryMember2020-12-310001624422ifrs-full:OfficeEquipmentMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2020-12-310001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:ConstructionInProgressMember2020-12-310001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembereryp:AdvancePaymentMember2020-12-310001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2020-12-310001624422ifrs-full:FixturesAndFittingsMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2021-01-012021-06-300001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:MachineryMember2021-01-012021-06-300001624422ifrs-full:OfficeEquipmentMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2021-01-012021-06-300001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:ConstructionInProgressMember2021-01-012021-06-300001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembereryp:AdvancePaymentMember2021-01-012021-06-300001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2021-01-012021-06-300001624422ifrs-full:FixturesAndFittingsMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2021-06-300001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:MachineryMember2021-06-300001624422ifrs-full:OfficeEquipmentMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2021-06-300001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:ConstructionInProgressMember2021-06-300001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembereryp:AdvancePaymentMember2021-06-300001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2021-06-300001624422ifrs-full:FixturesAndFittingsMember2020-12-310001624422ifrs-full:MachineryMember2020-12-310001624422ifrs-full:OfficeEquipmentMember2020-12-310001624422ifrs-full:ConstructionInProgressMember2020-12-310001624422eryp:AdvancePaymentMember2020-12-310001624422ifrs-full:FixturesAndFittingsMember2021-06-300001624422ifrs-full:MachineryMember2021-06-300001624422ifrs-full:OfficeEquipmentMember2021-06-300001624422ifrs-full:ConstructionInProgressMember2021-06-300001624422eryp:AdvancePaymentMember2021-06-300001624422ifrs-full:GrossCarryingAmountMemberifrs-full:BuildingsMember2020-12-310001624422ifrs-full:MachineryMemberifrs-full:GrossCarryingAmountMember2020-12-310001624422ifrs-full:VehiclesMemberifrs-full:GrossCarryingAmountMember2020-12-310001624422ifrs-full:GrossCarryingAmountMemberifrs-full:OfficeEquipmentMember2020-12-310001624422ifrs-full:GrossCarryingAmountMemberifrs-full:BuildingsMember2021-01-012021-06-300001624422ifrs-full:MachineryMemberifrs-full:GrossCarryingAmountMember2021-01-012021-06-300001624422ifrs-full:VehiclesMemberifrs-full:GrossCarryingAmountMember2021-01-012021-06-300001624422ifrs-full:GrossCarryingAmountMemberifrs-full:OfficeEquipmentMember2021-01-012021-06-300001624422ifrs-full:GrossCarryingAmountMemberifrs-full:BuildingsMember2021-06-300001624422ifrs-full:MachineryMemberifrs-full:GrossCarryingAmountMember2021-06-300001624422ifrs-full:VehiclesMemberifrs-full:GrossCarryingAmountMember2021-06-300001624422ifrs-full:GrossCarryingAmountMemberifrs-full:OfficeEquipmentMember2021-06-300001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:BuildingsMember2020-12-310001624422ifrs-full:MachineryMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2020-12-310001624422ifrs-full:VehiclesMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2020-12-310001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:OfficeEquipmentMember2020-12-310001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:BuildingsMember2021-01-012021-06-300001624422ifrs-full:MachineryMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2021-01-012021-06-300001624422ifrs-full:VehiclesMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2021-01-012021-06-300001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:OfficeEquipmentMember2021-01-012021-06-300001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:BuildingsMember2021-06-300001624422ifrs-full:MachineryMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2021-06-300001624422ifrs-full:VehiclesMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2021-06-300001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:OfficeEquipmentMember2021-06-300001624422ifrs-full:BuildingsMember2020-12-310001624422ifrs-full:MachineryMember2020-12-310001624422ifrs-full:VehiclesMember2020-12-310001624422ifrs-full:OfficeEquipmentMember2020-12-310001624422ifrs-full:BuildingsMember2021-06-300001624422ifrs-full:MachineryMember2021-06-300001624422ifrs-full:VehiclesMember2021-06-300001624422ifrs-full:OfficeEquipmentMember2021-06-300001624422eryp:DirectorsAndOfficersMember2021-06-300001624422eryp:TermDepositsMember2020-12-310001624422eryp:ConvertibleToCashMember2020-12-310001624422eryp:TermDepositsMember2021-06-300001624422eryp:ConvertibleToCashMember2021-06-300001624422eryp:RegisteredOfferingMember2021-04-012021-04-3000016244222022-01-012022-06-300001624422eryp:ConvertibleNotesMember2020-12-310001624422eryp:ConditionalAdvancesMember2020-12-310001624422eryp:BankLoansMember2020-12-310001624422eryp:OtherLiabilitiesMember2020-12-310001624422eryp:ConvertibleNotesMember2021-01-012021-06-300001624422eryp:ConditionalAdvancesMember2021-01-012021-06-300001624422eryp:BankLoansMember2021-01-012021-06-300001624422eryp:OtherLiabilitiesMember2021-01-012021-06-300001624422eryp:ConvertibleNotesMember2021-06-300001624422eryp:ConditionalAdvancesMember2021-06-300001624422eryp:BankLoansMember2021-06-300001624422eryp:OtherLiabilitiesMember2021-06-300001624422ifrs-full:NotLaterThanOneYearMember2021-06-300001624422ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember2021-06-300001624422ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember2021-06-300001624422ifrs-full:LaterThanFiveYearsMember2021-06-3000016244222021-03-022021-05-190001624422eryp:TrancheSixMember2021-03-020001624422eryp:TrancheSevenMember2021-05-190001624422eryp:TrancheSixAndSevenMemberifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2021-06-300001624422eryp:ConvertibleNotesMemberifrs-full:DerivativesMember2020-12-310001624422eryp:ConvertibleNotesMemberifrs-full:DerivativesMembereryp:TrancheSixMember2021-03-020001624422eryp:ConvertibleNotesMembereryp:TrancheSevenMemberifrs-full:DerivativesMember2021-05-190001624422eryp:ConvertibleNotesMemberifrs-full:DerivativesMember2021-06-300001624422eryp:ConvertibleNotesMemberifrs-full:DerivativesMember2020-12-312020-12-310001624422eryp:ConvertibleNotesMemberifrs-full:DerivativesMembereryp:TrancheSixMember2021-03-022021-03-020001624422eryp:ConvertibleNotesMembereryp:TrancheSevenMemberifrs-full:DerivativesMember2021-05-192021-05-190001624422eryp:ConvertibleNotesMemberifrs-full:DerivativesMember2021-06-302021-06-300001624422ifrs-full:DerivativesMembereryp:WarrantsMember2020-12-310001624422ifrs-full:DerivativesMembereryp:TrancheSixMembereryp:WarrantsMember2021-03-020001624422eryp:TrancheSevenMemberifrs-full:DerivativesMembereryp:WarrantsMember2021-05-190001624422ifrs-full:DerivativesMembereryp:WarrantsMember2021-06-300001624422ifrs-full:DerivativesMembereryp:WarrantsMember2020-12-312020-12-310001624422ifrs-full:DerivativesMembereryp:TrancheSixMembereryp:WarrantsMember2021-03-022021-03-020001624422eryp:TrancheSevenMemberifrs-full:DerivativesMembereryp:WarrantsMember2021-05-192021-05-190001624422ifrs-full:DerivativesMembereryp:WarrantsMember2021-06-302021-06-300001624422eryp:PriceOfUnderlyingShareMember2021-06-300001624422eryp:FinancialAssetsAtCarryingValueMember2020-12-310001624422ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2020-12-310001624422ifrs-full:FinancialAssetsAtFairValueMember2020-12-310001624422ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2020-12-310001624422eryp:FinancialLiabilitiesAtCarryingValueMember2020-12-310001624422ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2020-12-310001624422ifrs-full:FinancialLiabilitiesAtFairValueMember2020-12-310001624422ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2020-12-310001624422eryp:FinancialAssetsAtCarryingValueMember2021-06-300001624422ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2021-06-300001624422ifrs-full:FinancialAssetsAtFairValueMember2021-06-300001624422ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2021-06-300001624422eryp:FinancialLiabilitiesAtCarryingValueMember2021-06-300001624422ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2021-06-300001624422ifrs-full:FinancialLiabilitiesAtFairValueMember2021-06-300001624422ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2021-06-300001624422eryp:ExecutiveOfficersVPAndQualifiedPersonMember2020-01-012020-06-300001624422eryp:ExecutiveOfficersVPAndQualifiedPersonMember2021-01-012021-06-300001624422eryp:ExecutiveCommitteeMember2020-01-012020-06-300001624422eryp:ExecutiveCommitteeMember2021-01-012021-06-300001624422eryp:BoardOfDirectorsMember2020-01-012020-06-300001624422eryp:BoardOfDirectorsMember2021-01-012021-06-300001624422country:US2021-05-012021-05-31

UNITED STATES SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________
FORM 6-K
________________________
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of September 2021
Commission File Number: 001-38281

ERYTECH Pharma S.A.
(Translation of registrant’s name into English)

________________________

60 Avenue Rockefeller
69008 Lyon France
(Address of principal executive office)
________________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
 Form 20-F S         Form 40-F £  
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   £  
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):   £  




INCORPORATION BY REFERENCE
This Report on Form 6-K and Exhibit 99.1 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statement on Form F-3 (File No. 333-248953) and registration statements on Form S-8 (File Nos. 333-222673, 333-232670, 333-239429 and 333-255900), of ERYTECH Pharma S.A. (the “Company”) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.





Half-Year Financial Report for the Six Month Ended June 30, 2021
On September 20, 2021, the Company issued a press release announcing its financial results for the first half of 2021. The Company’s half-year financial report, including its condensed consolidated financial statements as of June 30, 2021, is attached to this Report on Form 6-K as Exhibit 99.1.






























EXHIBIT INDEX
ExhibitDescription
99.1
Half-Year Financial Report, including the Company’s condensed consolidated financial statements as of June 30, 2021
101.INS
XBRL Instance Document
101.SCH
XBRL Taxonomy Extension Schema Document
101.CAL
XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF
XBRL Taxonomy Extension Definition Linkbase Document
101.LAB
XBRL Taxonomy Extension Label Linkbase Document
101.PRE
XBRL Taxonomy Extension Presentation Linkbase Document





SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
ERYTECH Pharma S.A.
Date:
September 20, 2021
By:
/s/ Eric Soyer
Name Eric Soyer
Title: Chief Financial Officer and Chief Operating Officer



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings